Skip to main content
SSY Group Limited logo

SSY Group Limited — Investor Relations & Filings

Ticker · 2005 ISIN · KYG8406X1034 HKEX Manufacturing
Open in API
Filings indexed 1,213 across all filing types
Latest filing 2022-05-23 Declaration of Voting R…
Country HK Hong Kong
Listing HKEX 2005

About SSY Group Limited

http://www.ssygroup.com.hk

SSY Group Limited is an investment holding company specializing in the research, development, manufacturing, and sale of pharmaceutical products. The Group is a prominent manufacturer, with a core focus on producing a wide range of intravenous infusion solutions and finished drugs. Complementing its pharmaceutical offerings, the company also manufactures essential packaging materials, including non-PVC soft bags and PP plastic containers. SSY Group supplies its comprehensive product line, which often utilizes green production technologies aimed at reducing costs and power consumption, primarily to hospitals and medical institutions.

Recent filings

Filing Released Lang Actions
POLL RESULTS OF ANNUAL GENERAL MEETING 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'POLL RESULTS OF ANNUAL GENERAL MEETING 2022' and details the voting outcomes on various resolutions at the AGM, including adoption of financial statements, re-election of directors, appointment of auditors, dividend declaration, and approval of new articles of association. It references the AGM circular and notice, and provides detailed vote counts and percentages. The content is focused on announcing the official results of shareholder voting at the AGM rather than presenting the full AGM materials or the annual report itself. The document length is about 5273 characters, which is consistent with a detailed announcement of voting results rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-05-23 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement from the board of directors regarding an update on product development, specifically the approval of a drug product by a regulatory authority. It is not a financial report, earnings release, or any form of regulatory filing related to financial performance or governance. The document is short (1977 characters) and serves to inform shareholders and investors about business developments rather than financial results or corporate governance changes. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous filing that does not fit other specific categories.
2022-05-16 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors regarding the approval of a product (Pitavastatin calcium salt) by a regulatory authority (National Medical Products Administration of China). It is an update on product development and does not contain financial data, financial results, or detailed report content. The document is short (1533 characters) and serves to inform shareholders and investors about business developments rather than presenting a formal report or financial statements. It is not an Annual Report, Interim Report, Earnings Release, or any other detailed financial or regulatory filing. It is also not a report publication announcement since it does not mention any report being published or attached. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2022-05-13 English
Monthly Return of Equity Issuer on Movements in Securities
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly return concerning movements in securities for SSY Group Limited, including authorized share capital, issued shares, share options, and share repurchases. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content focuses on share capital changes, share repurchases, and confirmations related to securities issuance. There is no indication of financial performance data, earnings, management discussion, or audit information. The document is regulatory in nature, reporting share capital movements and share repurchases, which aligns with announcements of share capital changes rather than full financial reports or earnings releases. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length (8932 characters) and detailed data support it being a substantive filing rather than a brief announcement or certification.
2022-05-03 English
APPROVAL OF QUOTATION OF JIANGSU BEST NEW MEDICAL ON THE NEEQ
Capital/Financing Update Classification · 95% confidence The document is an announcement from SSY Group Limited regarding the approval of quotation of Jiangsu Best New Medical on the National Equities Exchange and Quotations (NEEQ). It discusses the spin-off and placing of new shares, the implications under the Listing Rules, and the expected size and structure of the placing. The document is relatively short (3213 characters) and serves as an update on capital market activities related to share issuance and listing approval. It does not contain financial statements or detailed financial analysis but rather informs about a capital market event and regulatory compliance related to share placement and listing. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-04-28 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by SSY Group Limited. It includes detailed information on repurchases and cancellations of shares, dates of changes, and confirmations by the board of directors. The document references compliance with listing rules of the Stock Exchange of Hong Kong and provides detailed disclosures about share repurchases and cancellations. This type of document is a regulatory disclosure about share capital changes and repurchases, not a full financial report or earnings release. It fits the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares (share repurchase/issuance). The document length and content confirm it is a detailed disclosure rather than a brief announcement or certification, supporting the POS classification.
2022-04-28 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.